Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Loxonin Suffers Most in Decrease in No. of Prescriptions Following Introduction of Generic Coefficient: Survey
August 21, 2015
- Announcement: 2015 Asia Pacific Meetings of ISMPP (Beijing on Aug. 30, Tokyo on Sept. 2)
August 20, 2015
- Anti-PD-L1 Antibody Atezolizumab Demonstrates Tumor Reduction Efficacy in NSCLC in PII Study: Roche
August 20, 2015
- Rheumatism Specialty Firm Ayumi Eyes Sales of 40-60 Billion Yen in 10 Years
August 19, 2015
- Shionogi Files Patent Suit over MSD’s HIV Drug
August 19, 2015
- Sawai’s Evista Generic Approved after Patent Battle
August 18, 2015
- Gene Techno Science, Mochida Tie Up for Joint Development of Biosimilars
August 18, 2015
- NBI Files for Micardis, Amlodipine, Diuretic Triple Combination Agents
August 18, 2015
- ASCO Immunotherapy Roundup - 7: Patient Group Hails Dawn of New Cancer Treatment Era
August 14, 2015
- Otsuka’s US Subsidiary Wins Patent Lawsuit over PBA Treatment
August 14, 2015
- Japan’s Diabetes Market to Exceed 600 Billion Yen in 2023: Fuji Keizai
August 14, 2015
- Kyowa Kirin Looks to Derive 40% of Sales Overseas by 2020, Split from Holdings Firm Won’t Happen: Pres.
August 13, 2015
- Hospira Japan’s Generic Oxaliplatin Approved for Gastric Cancer
August 13, 2015
- Ethical Drug Sales Up 9.8% in June: Crecon Report
August 13, 2015
- INCJ Invests 600 Million Yen in Drug Discovery Venture Founded by Tokyo Medical and Dental Univ.
August 12, 2015
- ASCO Immunotherapy Roundup - 6: CAR T-Cell Therapy Another Hot Field in Immuno-Oncology
August 12, 2015
- Quintiles to Set Up Unit for Medical Devices and Regenerative Medicines
August 12, 2015
- Biogen Japan Expects Continued Growth Past 2020 through Major New Drugs
August 11, 2015
- Long-Acting Injectable Version of Abilify Entering Accelerated Growth Phase: Pres. Higuchi of Otsuka Holdings
August 11, 2015
- Sublingual Immunotherapy Tablet for Pollinosis Shows Efficacy in PII/PIII Study in Japan: Torii
August 11, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…